

BPC-157/TB-500 Blend — Research Summary

Research Use Only. Not for human consumption. For laboratory/research reference purposes only.

Part of the Prolific Peptides Research Library — a summary of published third-party research, provided for informational and research purposes only. This content is separate from product listings and does not constitute a claim about any Prolific Peptides product's effects.

1. What It Is

The BPC-157/TB-500 Blend is a two-peptide research blend combining BPC-157 and TB-500 in a single lyophilized vial, formulated for its combined tissue-repair research focus. As with other blends, exact ratios vary by supplier; confirm the specific split on your product's Certificate of Analysis (COA).

2. Reported Effects in Research Literature

No published human data exists for this blend as a combined formulation — the rationale is mechanistic (two complementary tissue-repair pathways), not a tested combined outcome. Component-level evidence:

- BPC-157: Reported gastroprotective and anti-ulcer activity, angiogenesis (VEGFR2 pathway), tendon-ligament and soft-tissue repair, and anti-inflammatory signaling — almost entirely from preclinical/animal research concentrated in a single research group (University of Zagreb, Croatia).
- BPC-157 human data is very limited but growing: an unpublished Phase II ulcerative colitis trial, a discontinued 2015 Phase I safety trial (42 volunteers, results never published), a small 2025 IV pilot safety study (n=2), a 2024 published pilot study of intravesical BPC-157 for interstitial cystitis (12 patients, 10/12 complete symptom resolution — PMID 39325560), a retrospective case series of intra-articular BPC-157 for chronic knee pain (16 patients, 87.5% reporting relief), and one currently ongoing musculoskeletal trial (NCT07437547, acute hamstring strain). No completed, published randomized controlled human efficacy trial exists for BPC-157 as of 2026.
- TB-500: Reported to enhance cellular migration and cytoskeletal remodeling via actin-sequestering activity in preclinical wound-healing models, with reduced myofibroblast formation and organized connective tissue repair.
- Important distinction: most human clinical trial data (chronic wound Phase 2 trials, ophthalmic trials) was conducted on the full-length 43-amino-acid Thymosin Beta-4 protein, not the shorter 17-amino-acid TB-500 fragment sold under that name. No completed, published human trials exist specifically for the TB-500 fragment for any indication.
- Neither component is FDA-approved for any indication; both have been named in 2026 FDA compounding-list review discussions.
- PCAC update (July 23, 2026): The FDA's Pharmacy Compounding Advisory Committee voted to recommend both BPC-157 and TB-500 for inclusion on the 503A Bulk Drug Substances List (8–6, one abstention, for each), overriding FDA staff's own recommendation against inclusion. This is a non-binding advisory recommendation only. TB-500/thymosin-beta-4-class peptides are on the WADA Prohibited List, relevant for customers in tested athletic contexts.

3. Clinical & Preclinical Study References

Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." *Curr Pharm Des.* 2011;17(16):1612-32. PMID: 21548867

Ongoing trial: NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair

Discontinued Phase I: NCT02637284

Lee E, Walker C, Ayadi B. Interstitial cystitis pilot study. *Alt Ther Health Med.* 2024;30(10):12-17. PMID: 39325560

Ehrlich HP, Hazard SW 3rd. "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." *Ann N Y Acad Sci.* 2010;1194:118-24. PMID: 20536458

Scoping review: "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair." 2026.

Regulatory/Safety Note: BPC-157 and TB-500 are not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease, and the BPC-157/TB-500 Blend as a combined formulation has not been independently studied.

Verification Update: The same two new BPC-157 human pilot studies added to the standalone BPC-157 summary (interstitial cystitis, knee pain) apply here at the component level. No new TB-500-specific or combined-blend data was found.

This compound has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease in humans or animals.
This document is for informational and research purposes only. It does not constitute medical advice, dosing guidance, or an endorsement of human or veterinary use.
For full terms governing research use, see our RUO Policy at [ProlificPeptides.com](https://prolificpeptides.com).
This summary may not be reproduced, excerpted, or used as product labeling or marketing copy without written permission from Prolific Peptides, LLC.
Regulatory and research-status information reflects publicly available sources as of September 7, 2026, and may change.